Target intelligence / Profile preview

High mobility group nucleosomal binding domain 2 pseudogene 3 (HMGN2P3)

Target: HMGN2P3
Molecular classification: Pseudogene (non-coding DNA), retro-lncRNA

Overview

High mobility group nucleosomal binding domain 2 pseudogene 3 (HMGN2P3) is a human pseudogene derived from the HMGN2 gene, which is involved in chromatin structure and brain development. As a pseudogene, HMGN2P3 does not code for a functional protein, but its RNA transcript may participate in regulatory networks, such as acting as a competing endogenous RNA (ceRNA) or a microRNA sponge, potentially modulating the expression of other genes. There is no evidence to support a direct protein-coding or therapeutic function, nor is it considered a clinical biomarker or drug target. Its relevance, if any, is limited to possible indirect regulatory effects in gene expression, currently an area of active research but not clinical application[7][8][9].

Other names: HMGN2L3

Mechanism of action

Not applicable: No drugs target this pseudogene.

Biological functions

None (as a protein-coding gene)Possible regulatory noncoding RNA (ceRNA or lncRNA function)It does not encode a functional protein, but its RNA may regulate gene expression indirectly.

Disease associations

Other: There is no direct evidence linking HMGN2P3 itself to diseases. However, there is emerging, speculative evidence that some pseudogenes may indirectly play a role in neurodegenerative diseases (such as Huntington's, Alzheimer's, and Parkinson's disease) and potentially in cancer, by acting as ceRNAs

Safety considerations

None known. There are no known safety concerns or therapeutic challenges directly associated with this pseudogene. However, pseudogenes can occasionally complicate genetic assays (for example, causing PCR bias due to sequence similarity with functional genes)

Interacting drugs

None identified.

Biomarkers

None known.

Beyond the preview

Go deeper on High mobility group nucleosomal binding domain 2 pseudogene 3 (HMGN2P3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on High mobility group nucleosomal binding domain 2 pseudogene 3 (HMGN2P3).

Explore the full profile